AstraZeneca to pay milestone if Vimovo is approved
Posted on 30/06/2009 in Pharmaceutical Company Product News
AstraZeneca will pay its partner Pozen a $10 million (six million pounds) milestone payment if a drug is approved.
The latter company has submitted an application to the Food and Drug Administration for Vimovo (PN400) (enteric coated aproxen /esomeprazole magnesium) tablets.
Intended for use by patients who are at risk of developing certain types of ulcers, the therapy is being investigated for its effectiveness at easing the symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
The new drug application is based on clinical trials where PN400 met primary endpoints.
Compared to those receiving enteric coated naproxen, subjects who took the medication were less likely to suffer from edoscopically confirmed gastric ulcers.
Meanwhile, AstraZeneca and Bristol-Myers Squibb have received a positive opinion from the Committee for Medicinal Products for Human Use for Onglyza (saxagliptin) as a type 2 diabetes treatment.
It has been recommended for use in adults as an add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.
